NCT04934891View on ClinicalTrials.gov

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of ION547

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

March 24, 2021

Primary Completion Date

September 14, 2022

Study Completion Date

September 14, 2022

Conditions
Healthy Volunteers
Interventions
DRUG

ION547

ION547 will be administered by SC injection.

DRUG

Placebo

ION547-matching placebo will be administered by SC injection.

Trial Locations (1)

M9L 3A2

BioPharma Services, Inc., Toronto

Sponsors
All Listed Sponsors
lead

Ionis Pharmaceuticals, Inc.

INDUSTRY